Pharmacological Management of Orofacial Pain.
Journal
Drugs
ISSN: 1179-1950
Titre abrégé: Drugs
Pays: New Zealand
ID NLM: 7600076
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
accepted:
26
07
2023
medline:
21
9
2023
pubmed:
27
8
2023
entrez:
26
8
2023
Statut:
ppublish
Résumé
Orofacial pain is a category of complex disorders, including musculoskeletal, neuropathic and neurovascular disorders, that greatly affect the quality of life of the patient. These disorders are within the fields of dentistry and medicine and management can be challenging, requiring a referral to an orofacial pain specialist, essential for adequate evaluation, diagnosis, and care. Management is specific to the diagnosis and a treatment plan is developed with diverse pharmacological and non-pharmacological modalities. The pharmacological management of orofacial pain encompasses a vast array of medication classes and approaches. This includes anti-inflammatory drugs, muscle relaxants, anticonvulsants, antidepressants, and anesthetics. In addition, as adjunct therapy, different injections can be integrated into the management plan depending on the diagnosis and needs. These include trigger point injections, temporomandibular joint (TMJ) injections, and neurotoxin injections with botulinum toxin and nerve blocks. Multidisciplinary management is key for optimal care. New and safer therapeutic targets exclusively for the management of orofacial pain disorders are needed to offer better care for this patient population.
Identifiants
pubmed: 37632671
doi: 10.1007/s40265-023-01927-z
pii: 10.1007/s40265-023-01927-z
doi:
Substances chimiques
Anticonvulsants
0
Botulinum Toxins
EC 3.4.24.69
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1269-1292Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Klasser G, Romero-Reyes M. Orofacial pain guidelines for assessment, diagnosis, and management. 7th ed. Quintessence Publishing; 2023.
Haviv Y, Zini A, Etzioni Y, Klitinich V, Dobriyan A, Sharav Y, et al. The impact of chronic orofacial pain on daily life: the vulnerable patient and disruptive pain. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;123(1):58–66.
pubmed: 27727115
doi: 10.1016/j.oooo.2016.08.016
McMillan AS, Wong MC, Zheng J, Lam CL. Prevalence of orofacial pain and treatment seeking in Hong Kong Chinese. J Orofacial Pain Summer. 2006;20(3):218–25.
Lipton J, Ship J, Larach-Robinson D. Estimated prevalence and distribution of reported orofacial pain in the United States. J Am Dental Assoc. 1993;124(10):115–21 (1993 October 1).
doi: 10.14219/jada.archive.1993.0200
Macfarlane TV, Blinkhorn AS, Davies RM, Kincey J, Worthington HV. Oro-facial pain in the community: prevalence and associated impact. Commun Dent Oral Epidemiol. 2002;30(1):52–60.
doi: 10.1034/j.1600-0528.2002.300108.x
Romero-Reyes M, Uyanik JM. Orofacial pain management: current perspectives. J Pain Res. 2014;7:99–115.
pubmed: 24591846
pmcid: 3937250
doi: 10.2147/JPR.S37593
Heir GM, Ananthan S, Kalladka M, Kuchukulla M, Renton T. Persistent idiopathic dentoalveolar pain: Is it a central pain disorder? Dental Clin North Am. 2023;67(1):71–83.
doi: 10.1016/j.cden.2022.07.006
Tan HL, Smith JG, Hoffmann J, Renton T. A systematic review of treatment for patients with burning mouth syndrome. Cephalalgia. 2022;42(2):128–61.
pubmed: 34404247
doi: 10.1177/03331024211036152
Fillingim RB, Ohrbach R, Greenspan JD, Knott C, Diatchenko L, Dubner R, et al. Psychological factors associated with development of TMD: the OPPERA prospective cohort study. J Pain. 2013;14(12 Suppl):T75–90.
pubmed: 24275225
doi: 10.1016/j.jpain.2013.06.009
Fillingim RB, Slade GD, Greenspan JD, Dubner R, Maixner W, Bair E, et al. Long-term changes in biopsychosocial characteristics related to temporomandibular disorder: findings from the OPPERA study. Pain. 2018;159(11):2403–13.
pubmed: 30028791
pmcid: 6193833
doi: 10.1097/j.pain.0000000000001348
Facial Pain. National Institute of Dental and Craniofacial Research 2018 July, 2018; Available from: http://www.nidcr.nih.gov/DataStatistics/FindDataByTopic/FacialPain/
Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet J-P, et al. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Group. J Oral Facial Pain Headache. 2014;28(1):6–27.
pubmed: 24482784
pmcid: 4478082
doi: 10.11607/jop.1151
Slade GD, Ohrbach R, Greenspan JD, Fillingim RB, Bair E, Sanders AE, et al. Painful temporomandibular disorder: decade of discovery from OPPERA studies. J Dent Res. 2016;95(10):1084–92.
pubmed: 27339423
pmcid: 5004239
doi: 10.1177/0022034516653743
Glaros AG, Burton E. Parafunctional clenching, pain, and effort in temporomandibular disorders. J Behav Med. 2004;27(1):91–100.
pubmed: 15065478
doi: 10.1023/B:JOBM.0000013646.04624.8f
Glaros AG, Forbes M, Shanker J, Glass EG. Effect of parafunctional clenching on temporomandibular disorder pain and proprioceptive awareness. Cranio. 2000;18(3):198–204.
pubmed: 11202838
doi: 10.1080/08869634.2000.11746133
Ohrbach R, Fillingim RB, Mulkey F, Gonzalez Y, Gordon S, Gremillion H, et al. Clinical findings and pain symptoms as potential risk factors for chronic TMD: descriptive data and empirically identified domains from the OPPERA case-control study. J Pain. 2011;12(11 Suppl):T27–45.
pubmed: 22074750
pmcid: 3443556
doi: 10.1016/j.jpain.2011.09.001
Teruel A, Romero-Reyes M. Interplay of oral, mandibular, and facial disorders and migraine. Curr Pain Headache Rep. 2022. https://doi.org/10.1007/s11916-022-01054-6 .
doi: 10.1007/s11916-022-01054-6
pubmed: 35567662
International Classification of Orofacial Pain. 1st edition (ICOP). Cephalalgia. 2020;40(2):129–221.
Kuć J, Szarejko KD, Gołębiewska M. The prevalence and overlaps of temporomandibular disorders in patients with myofascial pain with referral—a pilot study. Int J Environ Res Public Health. 2021;18(18):9842.
pubmed: 34574764
pmcid: 8471332
doi: 10.3390/ijerph18189842
Golanska P, Saczuk K, Domarecka M, Kuć J, Lukomska-Szymanska M. Temporomandibular myofascial pain syndrome-aetiology and biopsychosocial modulation. A narrative review. Int J Environ Res Public Health. 2021;18(15):7807.
pubmed: 34360099
pmcid: 8345811
doi: 10.3390/ijerph18157807
Liu F, Steinkeler A. Epidemiology, diagnosis, and treatment of temporomandibular disorders. Dent Clin North Am. 2013;57(3):465–79.
pubmed: 23809304
doi: 10.1016/j.cden.2013.04.006
Valesan LF, Da-Cas CD, Réus JC, Denardin ACS, Garanhani RR, Bonotto D, et al. Prevalence of temporomandibular joint disorders: a systematic review and meta-analysis. Clin Oral Invest. 2021;25(2):441–53.
doi: 10.1007/s00784-020-03710-w
Okeson JP. Management of temporomandibular disorders and occlusion-E-book. Elsevier Health Sciences; 2019.
Kleykamp BA, Ferguson MC, McNicol E, Bixho I, Arnold LM, Edwards RR, et al. The prevalence of comorbid chronic pain conditions among patients with temporomandibular disorders: a systematic review. J Am Dent Assoc. 2022;153(3):241–50 (e10).
pubmed: 34952681
doi: 10.1016/j.adaj.2021.08.008
Franco AL, Goncalves DA, Castanharo SM, Speciali JG, Bigal ME, Camparis CM. Migraine is the most prevalent primary headache in individuals with temporomandibular disorders. J Orofacial Pain. 2011;24(3):287–92.
Thomas DC, Khan J, Manfredini D, Ailani J. Temporomandibular joint disorder comorbidities. Dent Clin North Am. 2023;67(2):379–92.
pubmed: 36965938
doi: 10.1016/j.cden.2022.10.005
Karamat A, Smith JG, Melek LNF, Renton T. Psychologic impact of chronic orofacial pain: a critical review. J Oral Facial Pain Headache. 2022;36(2):103–40.
pubmed: 35943323
doi: 10.11607/ofph.3010
Reis PHF, Laxe LAC, Lacerda-Santos R, Münchow EA. Distribution of anxiety and depression among different subtypes of temporomandibular disorder: a systematic review and meta-analysis. J Oral Rehabil. 2022;49(7):754–67.
pubmed: 35398904
doi: 10.1111/joor.13331
De Leeuw RaK GD. Orofacial pain guidelines for assessment, diagnosis, and managment. 6th ed. Chicago: Quintessence Books; 2018.
Ohrbach R, Dworkin SF. Five-year outcomes in TMD: relationship of changes in pain to changes in physical and psychological variables. Pain. 1998;74(2–3):315–26.
pubmed: 9520246
doi: 10.1016/S0304-3959(97)00194-2
Kandasamy S, Greene CS. The evolution of temporomandibular disorders: a shift from experience to evidence. J Oral Pathol Med. 2020;49(6):461–9.
pubmed: 32585044
doi: 10.1111/jop.13080
Noma N, Watanabe Y, Shimada A, Usuda S, Iida T, Shimada A, et al. Effects of cognitive behavioral therapy on orofacial pain conditions. J Oral Sci. 2021;63(1):4–7.
doi: 10.2334/josnusd.20-0437
Bair E, Gaynor S, Slade GD, Ohrbach R, Fillingim RB, Greenspan JD, et al. Identification of clusters of individuals relevant to temporomandibular disorders and other chronic pain conditions: the OPPERA study. Pain. 2016;157(6):1266–78.
pubmed: 26928952
pmcid: 4949303
doi: 10.1097/j.pain.0000000000000518
Van Bellinghen X, Idoux-Gillet Y, Pugliano M, Strub M, Bornert F, Clauss F, et al. Temporomandibular joint regenerative medicine. Int J Mol Sci. 2018;19(2):446. https://doi.org/10.3390/ijms19020446 . PMID: 29393880; PMCID: PMC5855668.
Montinaro F, Nucci L, d’Apuzzo F, Perillo L, Chiarenza MC, Grassia V. Oral nonsteroidal anti-inflammatory drugs as treatment of joint and muscle pain in temporomandibular disorders: a systematic review. Cranio. 2022;7:1–10.
doi: 10.1080/08869634.2022.2031688
Kulkarni S, Thambar S, Arora H. Evaluating the effectiveness of nonsteroidal anti-inflammatory drug(s) for relief of pain associated with temporomandibular joint disorders: a systematic review. Clin Exp Dental Res. 2020;6(1):134–46.
doi: 10.1002/cre2.241
Ta LE, Dionne RA. Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen. Pain. 2004;111(1–2):13–21.
pubmed: 15327804
doi: 10.1016/j.pain.2004.04.029
Andre A, Kang J, Dym H. Pharmacologic treatment for temporomandibular and temporomandibular joint disorders. Oral Maxillofac Surg Clin North Am. 2022;34(1):49–59.
pubmed: 34598856
doi: 10.1016/j.coms.2021.08.001
Häggman-Henrikson B, Alstergren P, Davidson T, Högestätt ED, Östlund P, Tranaeus S, et al. Pharmacological treatment of oro-facial pain—health technology assessment including a systematic review with network meta-analysis. J Oral Rehabil. 2017;44(10):800–26.
pubmed: 28884860
doi: 10.1111/joor.12539
Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004;28(2):140–75.
pubmed: 15276195
doi: 10.1016/j.jpainsymman.2004.05.002
Herman CR, Schiffman EL, Look JO, Rindal DB. The effectiveness of adding pharmacologic treatment with clonazepam or cyclobenzaprine to patient education and self-care for the treatment of jaw pain upon awakening: a randomized clinical trial. J Orofacial Pain. 2002;16(1):64–70.
pubmed: 11889661
Rizzatti-Barbosa CM, Nogueira MT, de Andrade ED, Ambrosano GM, de Barbosa JR. Clinical evaluation of amitriptyline for the control of chronic pain caused by temporomandibular joint disorders. Cranio. 2003;21(3):221–5.
pubmed: 12889679
doi: 10.1080/08869634.2003.11746254
Kimos P, Biggs C, Mah J, Heo G, Rashiq S, Thie NM, et al. Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial. Pain. 2007;127(1–2):151–60.
pubmed: 17030096
doi: 10.1016/j.pain.2006.08.028
Haviv Y, Rettman A, Aframian D, Sharav Y, Benoliel R. Myofascial pain: an open study on the pharmacotherapeutic response to stepped treatment with tricyclic antidepressants and gabapentin. J Oral Facial Pain Headache. 2015;29(2):144–51.
pubmed: 25905532
doi: 10.11607/ofph.1408
Müggenborg F, de Castro Carletti EM, Dennett L, de Oliveira-Souza AIS, Mohamad N, Licht G, et al. Effectiveness of manual trigger point therapy in patients with myofascial trigger points in the orofacial region-a systematic review. Life (Basel, Switzerland). 2023;13(2):336.
pubmed: 36836693
pmcid: 9965624
Machado E, Machado P, Wandscher VF, Marchionatti AME, Zanatta FB, Kaizer OB. A systematic review of different substance injection and dry needling for treatment of temporomandibular myofascial pain. Int J Oral Maxillofac Surg. 2018;47(11):1420–32.
pubmed: 29801994
doi: 10.1016/j.ijom.2018.05.003
Nouged E, Dajani J, Ku B, Al-Eryani K, Padilla M, Enciso R. Local anesthetic injections for the short-term treatment of head and neck myofascial pain syndrome: a systematic review with meta-analysis. J Oral Facial Pain Headache. 2019;33(2):183–98.
pubmed: 30893405
doi: 10.11607/ofph.2277
Tough EA, White AR, Cummings TM, Richards SH, Campbell JL. Acupuncture and dry needling in the management of myofascial trigger point pain: a systematic review and meta-analysis of randomised controlled trials. Eur J Pain. 2009;13(1):3–10.
pubmed: 18395479
doi: 10.1016/j.ejpain.2008.02.006
Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack AA. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13.
pubmed: 29404713
pmcid: 5799088
doi: 10.1186/s10194-018-0840-8
Awan KH, Patil S, Alamir AWH, Maddur N, Arakeri G, Carrozzo M, et al. Botulinum toxin in the management of myofascial pain associated with temporomandibular dysfunction. J Oral Pathol Med. 2019;48(3):192–200.
pubmed: 30604895
doi: 10.1111/jop.12822
Delcanho R, Val M, Guarda Nardini L, Manfredini D. Botulinum toxin for treating temporomandibular disorders: What is the evidence? J Oral Facial Pain Headache. 2022;36(1):6–20.
pubmed: 35298571
doi: 10.11607/ofph.3023
Connelly ST, Myung J, Gupta R, Tartaglia GM, Gizdulich A, Yang J, et al. Clinical outcomes of Botox injections for chronic temporomandibular disorders: do we understand how Botox works on muscle, pain, and the brain? Int J Oral Maxillofac Surg. 2017;46(3):322–7.
pubmed: 27908491
doi: 10.1016/j.ijom.2016.11.004
Muñoz Lora VRM, Del Bel Cury AA, Jabbari B, Lacković Z. Botulinum toxin type A in dental medicine. J Dent Res. 2019;98(13):1450–7.
pubmed: 31533008
doi: 10.1177/0022034519875053
Wehling P, Evans C, Wehling J, Maixner W. Effectiveness of intra-articular therapies in osteoarthritis: a literature review. Therapeutic Adv Musculoskelet Dis. 2017;9(8):183–96.
doi: 10.1177/1759720X17712695
Clark GT, Dionne RA. Orofacial pain: a guide to medications and management; 2013.
Gencer ZK, Özkiriş M, Okur A, Korkmaz M, Saydam L. A comparative study on the impact of intra-articular injections of hyaluronic acid, tenoxicam and betametazon on the relief of temporomandibular joint disorder complaints. J Cranio-Maxillo-Facial Surg. 2014;42(7):1117–21.
doi: 10.1016/j.jcms.2014.01.041
de Souza RF, Lovato da Silva CH, Nasser M, Fedorowicz Z, Al-Muharraqi MA. Interventions for the management of temporomandibular joint osteoarthritis. Cochrane Database Syst Rev. 2012;2012(4): Cd007261.
pubmed: 22513948
pmcid: 6513203
Isacsson G, Schumann M, Nohlert E, Mejersjö C, Tegelberg Å. Pain relief following a single-dose intra-articular injection of methylprednisolone in the temporomandibular joint arthralgia—a multicentre randomised controlled trial. J Oral Rehabil. 2019;46(1):5–13.
pubmed: 30240024
doi: 10.1111/joor.12718
Yapici-Yavuz G, Şimşek-Kaya G, Oğul H. A comparison of the effects of Methylprednisolone Acetate, Sodium Hyaluronate and Tenoxicam in the treatment of non-reducing disc displacement of the temporomandibular joint. Medicina oral, patologia oral y cirugia bucal. 2018;23(3):e351–8.
pubmed: 29680845
pmcid: 5945235
Skármeta NP, Hormazábal FA, Alvarado J, Rodriguez AM. Subcutaneous lipoatrophy and skin depigmentation secondary to TMJ intra-articular corticosteroid injection. J Oral Maxillofac Surg. 2017;75(12):2540 (e1-.e5).
doi: 10.1016/j.joms.2017.07.174
Schindler C, Paessler L, Eckelt U, Kirch W. Severe temporomandibular dysfunction and joint destruction after intra-articular injection of triamcinolone. J Oral Pathol Med. 2005;34(3):184–6.
pubmed: 15689233
doi: 10.1111/j.1600-0714.2004.00247.x
Nitzan DW. The process of lubrication impairment and its involvement in temporomandibular joint disc displacement: a theoretical concept. J Oral Maxillofac Surg. 2001;59(1):36–45.
pubmed: 11152188
doi: 10.1053/joms.2001.19278
Guarda-Nardini L, Cadorin C, Frizziero A, Ferronato G, Manfredini D. Comparison of 2 hyaluronic acid drugs for the treatment of temporomandibular joint osteoarthritis. J Oral Maxillofac Surg. 2012;70(11):2522–30.
pubmed: 22939642
doi: 10.1016/j.joms.2012.07.020
Iturriaga V, Bornhardt T, Manterola C, Brebi P. Effect of hyaluronic acid on the regulation of inflammatory mediators in osteoarthritis of the temporomandibular joint: a systematic review. Int J Oral Maxillofac Surg. 2017;46(5):590–5.
pubmed: 28228347
doi: 10.1016/j.ijom.2017.01.014
Korkmaz YT, Altıntas NY, Korkmaz FM, Candırlı C, Coskun U, Durmuslar MC. Is hyaluronic acid injection effective for the treatment of temporomandibular joint disc displacement with reduction? J Oral Maxillofac Surg. 2016;74(9):1728–40.
pubmed: 27058964
doi: 10.1016/j.joms.2016.03.005
Fonseca R, Januzzi E, Ferreira LA, Grossmann E, Carvalho ACP, de Oliveira PG, et al. Effectiveness of sequential viscosupplementation in temporomandibular joint internal derangements and symptomatology: a case series. Pain Res Manage. 2018;2018:5392538.
doi: 10.1155/2018/5392538
Li C, Long X, Deng M, Li J, Cai H, Meng Q. Osteoarthritic changes after superior and inferior joint space injection of hyaluronic acid for the treatment of temporomandibular joint osteoarthritis with anterior disc displacement without reduction: a cone-beam computed tomographic evaluation. J Oral Maxillofac Surg. 2015;73(2):232–44.
pubmed: 25579006
doi: 10.1016/j.joms.2014.08.034
Ferreira N, Masterson D, Lopes de Lima R, de Souza-Moura B, Oliveira AT, Kelly da Silvafidalgo T, et al. Efficacy of viscosupplementation with hyaluronic acid in temporomandibular disorders: a systematic review. J Cranio-Maxillo-Facial Surg. 2018;46(11):1943–52.
doi: 10.1016/j.jcms.2018.08.007
Dhillon MS, Behera P, Patel S, Shetty V. Orthobiologics and platelet rich plasma. Indian J Orthopaedics. 2014;48(1):1–9.
doi: 10.4103/0019-5413.125477
Zotti F, Albanese M, Rodella LF, Nocini PF. Platelet-rich plasma in treatment of temporomandibular joint dysfunctions: narrative review. Int J Mol Sci. 2019;20(2):277.
pubmed: 30641957
pmcid: 6358929
doi: 10.3390/ijms20020277
Bousnaki M, Bakopoulou A, Koidis P. Platelet-rich plasma for the therapeutic management of temporomandibular joint disorders: a systematic review. Int J Oral Maxillofac Surg. 2018;47(2):188–98.
pubmed: 29066000
doi: 10.1016/j.ijom.2017.09.014
Hegab AF, Ali HE, Elmasry M, Khallaf MG. Platelet-rich plasma injection as an effective treatment for temporomandibular joint osteoarthritis. J Oral Maxillofac Surg. 2015;73(9):1706–13.
pubmed: 25882438
doi: 10.1016/j.joms.2015.03.045
Gokçe Kutuk S, Gökçe G, Arslan M, Özkan Y, Kütük M, Kursat AO. Clinical and radiological comparison of effects of platelet-rich plasma, hyaluronic acid, and corticosteroid injections on temporomandibular joint osteoarthritis. J Craniofac Surg. 2019;30(4):1144–8.
pubmed: 31166260
doi: 10.1097/SCS.0000000000005211
Hancı M, Karamese M, Tosun Z, Aktan TM, Duman S, Savaci N. Intra-articular platelet-rich plasma injection for the treatment of temporomandibular disorders and a comparison with arthrocentesis. J Cranio-Maxillo-Facial Surg. 2015;43(1):162–6.
doi: 10.1016/j.jcms.2014.11.002
Liapaki A, Thamm JR, Ha S, Monteiro J, McCain JP, Troulis MJ, et al. Is there a difference in treatment effect of different intra-articular drugs for temporomandibular joint osteoarthritis? A systematic review of randomized controlled trials. Int J Oral Maxillofac Surg. 2021;50(9):1233–43.
pubmed: 33642154
doi: 10.1016/j.ijom.2021.01.019
Zarate MA, Frusso RD, Reeves KD, Cheng AL, Rabago D. Dextrose prolotherapy versus lidocaine injection for temporomandibular dysfunction: a pragmatic randomized controlled trial. J Altern Complement Med. 2020;26(11):1064–73.
pubmed: 32780636
doi: 10.1089/acm.2020.0207
Sit RW, Reeves KD, Zhong CC, Wong CHL, Wang B, Chung VC, et al. Efficacy of hypertonic dextrose injection (prolotherapy) in temporomandibular joint dysfunction: a systematic review and meta-analysis. Sci Rep. 2021;11(1):14638.
pubmed: 34282199
pmcid: 8289855
doi: 10.1038/s41598-021-94119-2
Bouloux G, Koslin MG, Ness G, Shafer D. Temporomandibular joint surgery. J Oral Maxillofac Surg. 2017;75(8s):e195–223.
pubmed: 28728730
doi: 10.1016/j.joms.2017.04.027
Haanpää M, Attal N, Backonja M, Baron R, Bennett M, Bouhassira D, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain. 2011;152(1):14–27.
pubmed: 20851519
doi: 10.1016/j.pain.2010.07.031
Eliav E MM. Management of neuropathic pain. In: Sessle B LG, Lund J, Dubner R, editors., editor. Orofacial pain From basic science to clinical management Chicago: Quintessence; 2008. p. 195–202.
Renton T. Persistent pain after dental surgery. Rev Pain. 2011;5(1):8–17.
pubmed: 26526800
pmcid: 4590080
doi: 10.1177/204946371100500103
Delcanho R, Moncada E. Persistent pain after dental implant placement: a case of implant-related nerve injury. J Am Dent Assoc. 2014;145(12):1268–71.
pubmed: 25429041
doi: 10.14219/jada.2014.210
Mills EP, Keay KA, Henderson LA. brainstem pain-modulation circuitry and its plasticity in neuropathic pain: insights from human brain imaging investigations. Front Pain Res (Lausanne, Switzerland). 2021;2: 705345.
pmcid: 8915745
doi: 10.3389/fpain.2021.705345
Sessle BJ. Chronic orofacial pain: models, mechanisms, and genetic and related environmental influences. Int J Mol Sci. 2021;22(13):7112.
pubmed: 34281164
pmcid: 8268972
doi: 10.3390/ijms22137112
Korczeniewska OA, Kohli D, Benoliel R, Baddireddy SM, Eliav E. Pathophysiology of post-traumatic trigeminal neuropathic pain. Biomolecules. 2022;12(12):1753.
pubmed: 36551181
pmcid: 9775491
doi: 10.3390/biom12121753
Ossipov MH, Morimura K, Porreca F. Descending pain modulation and chronification of pain. Curr Opin Support Palliat Care. 2014;8(2):143–51.
pubmed: 24752199
pmcid: 4301419
doi: 10.1097/SPC.0000000000000055
Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3(1):17002 (2017/02/16).
pubmed: 28205574
pmcid: 5371025
doi: 10.1038/nrdp.2017.2
Penlington C, Araújo-Soares V, Durham J. Predicting persistent orofacial pain: the role of illness perceptions, anxiety, and depression. JDR Clin Transl Res. 2019;5(1):40–9 (2017/02/16).
doi: 10.1177/2380084419846447
Van der Cruyssen F, Peeters F, Gill T, De Laat A, Jacobs R, Politis C, et al. Signs and symptoms, quality of life and psychosocial data in 1331 post-traumatic trigeminal neuropathy patients seen in two tertiary referral centres in two countries. J Oral Rehabil. 2020;47(10):1212–21.
pubmed: 32687637
pmcid: 7540026
doi: 10.1111/joor.13058
Ziegeler C, Brauns G, May A. Characteristics and natural disease history of persistent idiopathic facial pain, trigeminal neuralgia, and neuropathic facial pain. Headache. 2021;61(9):1441–2151.
pubmed: 34618363
doi: 10.1111/head.14212
Truelove E. Management is sues of neuropathic trigeminal pain from a dental perspective. J Orofac Pain. 2004;18(4):374–80.
pubmed: 15636023
Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
doi: 10.1177/0333102417738202
McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013;2013(8): Cd006146.
pubmed: 23986501
pmcid: 6353125
Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpaa ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clinic Proc Mayo Clin. 2010;85(3 Suppl):S3-14.
doi: 10.4065/mcp.2009.0649
Attal N. Pharmacological treatments of neuropathic pain: The latest recommendations. Rev Neurol (Paris). 2019;175(1–2):46–50.
pubmed: 30318260
doi: 10.1016/j.neurol.2018.08.005
Bendtsen L, Zakrzewska JM, Heinskou TB, Hodaie M, Leal PRL, Nurmikko T, et al. Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. Lancet Neurol. 2020;19(9):784–96.
pubmed: 32822636
doi: 10.1016/S1474-4422(20)30233-7
Koopman JS, Dieleman JP, Huygen FJ, de Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain. 2009;147(1–3):122–7.
pubmed: 19783099
doi: 10.1016/j.pain.2009.08.023
Araya EI, Claudino RF, Piovesan EJ, Chichorro JG. Trigeminal neuralgia: basic and clinical aspects. Curr Neuropharmacol. 2020;18(2):109–19.
pubmed: 31608834
pmcid: 7324879
doi: 10.2174/1570159X17666191010094350
VanderPluym J, Richer L. Tic versus TAC: differentiating the neuralgias (trigeminal neuralgia) from the cephalalgias (SUNCT and SUNA). Curr Pain Headache Rep. 2014;19(2):473 (2014/12/11).
doi: 10.1007/s11916-014-0473-9
Lambru G, Zakrzewska J, Matharu M. Trigeminal neuralgia: a practical guide. Pract Neurol. 2021;21(5):392–402.
pubmed: 34108244
pmcid: 8461413
doi: 10.1136/practneurol-2020-002782
Zakrzewska JM, Wu N, Lee JYK, Werneburg B, Hoffman D, Liu Y. Characterizing treatment utilization patterns for trigeminal neuralgia in the United States. Clin J Pain. 2018;34(8):691–9.
pubmed: 29443722
doi: 10.1097/AJP.0000000000000595
Zakrzewska JM. Medical management of trigeminal neuropathic pains. Expert Opin Pharmacother. 2010;11(8):1239–54.
pubmed: 20426709
doi: 10.1517/14656561003767449
Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev. 2017;12(12): Cd007963.
pubmed: 29199767
Wiffen PJ, Derry S, Moore RA, McQuay HJ. Carbamazepine for acute and chronic pain in adults. Cochrane Database Syst Rev. 2011;19(1): Cd005451.
Bendtsen L, Zakrzewska JM, Abbott J, Braschinsky M, Di Stefano G, Donnet A, et al. European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol. 2019;26(6):831–49.
pubmed: 30860637
doi: 10.1111/ene.13950
Moore D, Chong MS, Shetty A, Zakrzewska JM. A systematic review of rescue analgesic strategies in acute exacerbations of primary trigeminal neuralgia. Br J Anaesth. 2019;123(2):e385–96.
pubmed: 31208761
pmcid: 6676170
doi: 10.1016/j.bja.2019.05.026
Wang QP, Bai M. Topiramate versus carbamazepine for the treatment of classical trigeminal neuralgia. CNS Drugs. 2011;25(10):847–57 (2011/10/01).
pubmed: 21936587
doi: 10.2165/11595590-000000000-00000
Anand KS, Dhikav V, Prasad A, Shewtengna. Efficacy, safety and tolerability of duloxetine in idiopathic trigeminal neuralgia. J Indian Med Assoc. 2011;109(4):264–6.
pubmed: 22187799
Obermann M. Update on the challenges of treating trigeminal neuralgia. Orphan Drug. 2015. https://doi.org/10.2147/ODRR.S53046 .
doi: 10.2147/ODRR.S53046
Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008;9(10):1543–6.
pubmed: 18855540
doi: 10.2217/14622416.9.10.1543
Mushiroda T, Takahashi Y, Onuma T, Yamamoto Y, Kamei T, Hoshida T, et al. Association of HLA-A*31:01 screening with the incidence of carbamazepine-induced cutaneous adverse reactions in a Japanese population. JAMA Neurol. 2018;75(7):842–9.
pubmed: 29610831
pmcid: 6145764
doi: 10.1001/jamaneurol.2018.0278
Chen CB, Hsiao YH, Wu T, Hsih MS, Tassaneeyakul W, Jorns TP, et al. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology. 2017;88(1):78–86.
pubmed: 27913699
doi: 10.1212/WNL.0000000000003453
Xu R, Nair SK, Shah PP, Kannapadi N, Materi J, Alomari S, et al. A potential role for steroids in acute pain management in patients with trigeminal neuralgia. World Neurosurg. 2022;167:e1291–8.
pubmed: 36113711
doi: 10.1016/j.wneu.2022.09.025
Mauskop A. Trigeminal neuralgia (tic douloureux). J Pain Symptom Manage. 1993;8(3):148–54 (1993/04/01/).
pubmed: 8326165
doi: 10.1016/0885-3924(93)90143-J
DMKG study group. Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis. J Neurol. 2003;250(5):542–5. https://doi.org/10.1007/s00415-003-1032-1 . PMID: 12736732.
Pfau G, Brinkers M, Treuheit T, Kretzschmar M, Sentürk M, Hachenberg T. Misoprostol as a therapeutic option for trigeminal neuralgia in patients with multiple sclerosis. Pain Med. 2012;13(10):1377–8.
pubmed: 22925476
doi: 10.1111/j.1526-4637.2012.01472.x
Heinskou T, Maarbjerg S, Rochat P, Wolfram F, Jensen RH, Bendtsen L. Trigeminal neuralgia–a coherent cross-specialty management program. J Headache Pain. 2015;16:66.
pubmed: 26183265
pmcid: 4504871
doi: 10.1186/s10194-015-0550-4
Hadley GR, Gayle JA, Ripoll J, Jones MR, Argoff CE, Kaye RJ, et al. Post-herpetic neuralgia: a review. Curr Pain Headache Rep. 2016;20(3):17.
pubmed: 26879875
doi: 10.1007/s11916-016-0548-x
Truini A, Galeotti F, Haanpaa M, Zucchi R, Albanesi A, Biasiotta A, et al. Pathophysiology of pain in postherpetic neuralgia: a clinical and neurophysiological study. Pain. 2008;140(3):405–10.
pubmed: 18954941
doi: 10.1016/j.pain.2008.08.018
Shrestha M, Chen A. Modalities in managing postherpetic neuralgia. Korean J Pain. 2018;31(4):235–43.
pubmed: 30310548
pmcid: 6177534
doi: 10.3344/kjp.2018.31.4.235
Gan EY, Tian EA, Tey HL. Management of herpes zoster and post-herpetic neuralgia. Am J Clin Dermatol. 2013;14(2):77–85.
pubmed: 23456596
doi: 10.1007/s40257-013-0011-2
Tay AB, Zuniga JR. Clinical characteristics of trigeminal nerve injury referrals to a university centre. Int J Oral Maxillofac Surg. 2007;36(10):922–7.
pubmed: 17875382
doi: 10.1016/j.ijom.2007.03.012
Neal TW, Zuniga JR. Post-traumatic trigeminal neuropathic pain: factors affecting surgical treatment outcomes. Front Oral Health. 2022;3: 904785.
pubmed: 35874124
pmcid: 9301486
doi: 10.3389/froh.2022.904785
Baad-Hansen L, Benoliel R. Neuropathic orofacial pain: facts and fiction. Cephalalgia. 2017;37(7):670–9.
pubmed: 28403646
doi: 10.1177/0333102417706310
Benoliel R, Kahn J, Eliav E. Peripheral painful traumatic trigeminal neuropathies. Oral Dis. 2012;18(4):317–32.
pubmed: 22212350
doi: 10.1111/j.1601-0825.2011.01883.x
Lewis MAO, Sankar V, De Laat A, Benoliel R. Management of neuropathic orofacial pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontics. 2007;103:S32 (e1-S.e24).
doi: 10.1016/j.tripleo.2006.10.014
Jia Z, Yu J, Zhao C, Ren H, Luo F. Outcomes and predictors of response of duloxetine for the treatment of persistent idiopathic dentoalveolar pain: a retrospective multicenter observational study. J Pain Res. 2022;15:3031–41.
pubmed: 36193165
pmcid: 9526422
doi: 10.2147/JPR.S379430
Forssell H, Tasmuth T, Tenovuo O, Hampf G, Kalso E. Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. J Orofac Pain. 2004;18(2):131–7.
pubmed: 15250433
Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;2015(7): Cd008242.
pubmed: 26146793
pmcid: 6447238
Clarkson E, Jung E. Atypical facial pain. Dental Clin North Am. 2020;64(1):249–53 (2020/01/01/).
doi: 10.1016/j.cden.2019.08.014
Forssell H, Jääskeläinen S, List T, Svensson P, Baad-Hansen L. An update on pathophysiological mechanisms related to idiopathic oro-facial pain conditions with implications for management. J Oral Rehabil. 2015;42(4):300–22.
pubmed: 25483941
doi: 10.1111/joor.12256
Koopman JSHA, Dieleman JP, Huygen FJ, de Mos M, Martin CGM, Sturkenboom MCJM. Incidence of facial pain in the general population. Pain. 2009;147(1-2–3):122–7.
pubmed: 19783099
doi: 10.1016/j.pain.2009.08.023
Forssell H, Tenovuo O, Silvoniemi P, Jääskeläinen SK. Differences and similarities between atypical facial pain and trigeminal neuropathic pain. Neurology. 2007;69(14):1451–9.
pubmed: 17909158
doi: 10.1212/01.wnl.0000277274.83301.c0
Herrero Babiloni A, Nixdorf DR, Moana-Filho EJ. Persistent dentoalveolar pain disorder: a putative intraoral chronic overlapping pain condition. Oral Dis. 2020;26(8):1601–9.
pubmed: 31797486
doi: 10.1111/odi.13248
Benoliel R, Gaul C. Persistent idiopathic facial pain. Cephalalgia. 2017;37(7):680–91 (2017/06/01).
pubmed: 28425324
doi: 10.1177/0333102417706349
Neuman DL, Chadwick AL. Utilization of low-dose naltrexone for burning mouth syndrome: a case report. A&A Practice. 2021;15(5): e01475.
doi: 10.1213/XAA.0000000000001475
Sangalli L, Miller CS. Low-dose naltrexone for treatment of burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol. 2023;135(4):e83–8 (2023/04/01/).
pubmed: 35851249
doi: 10.1016/j.oooo.2022.04.048
Padilla M, Clark GT, Merrill RL. Topical medications for orofacial neuropathic pain: a review. J Am Dent Assoc. 2000;131(2):184–95 (2000 February 1).
pubmed: 10680386
doi: 10.14219/jada.archive.2000.0146
Heir GM, Katzmann G, Covalesky B, Cammarata J, Mangal J, Kalladka M, et al. Use of compounded topical medications for treatment of orofacial pain: a narrative review. J Oral Maxillofac Anesth. 2022;1. https://joma.amegroups.org/article/view/5773 .
Casale R, Symeonidou Z, Bartolo M. Topical treatments for localized neuropathic pain. Curr Pain Headache Rep. 2017;21(3):15.
pubmed: 28271334
pmcid: 5340828
doi: 10.1007/s11916-017-0615-y
Rossella I, Alessandro V, Naman R, Gary K, Hervé SY. Topical clonazepam for burning mouth syndrome: Is it efficacious in patients with anxiety or depression? J Oral Rehabil. 2022;49(1):54–61.
pubmed: 34716948
doi: 10.1111/joor.13275
Kuten-Shorrer M, Treister NS, Stock S, Kelley JM, Ji YD, Woo SB, et al. Topical clonazepam solution for the management of burning mouth syndrome: a retrospective study. J Oral Facial Pain Headache. 2017;31(3):257–63.
pubmed: 28738111
doi: 10.11607/ofph.1754
Dinan JE, Smith A, Hawkins JM. Trigeminal neuralgia with extraoral trigger zone successfully treated with intraoral injections of botulinum toxin: a case report. Clin Neuropharmacol. 2020;43(5):162–3.
pubmed: 32947428
doi: 10.1097/WNF.0000000000000399
Burmeister J, Holle D, Bock E, Ose C, Diener HC, Obermann M. Botulinum neurotoxin type A in the treatment of classical Trigeminal Neuralgia (BoTN): study protocol for a randomized controlled trial. Trials. 2015;3(16):550.
doi: 10.1186/s13063-015-1052-z
Wei J, Zhu X, Yang G, Shen J, Xie P, Zuo X, et al. The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: a meta-analysis of randomized controlled trials. Brain and behavior. 2019;9(10): e01409.
pubmed: 31541518
pmcid: 6790324
doi: 10.1002/brb3.1409
Herrero Babiloni A, Kapos FP, Nixdorf DR. Intraoral administration of botulinum toxin for trigeminal neuropathic pain. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121(6):e148–53.
pubmed: 27181448
doi: 10.1016/j.oooo.2016.03.013
Blumenfeld A, Ashkenazi A, Napchan U, Bender SD, Klein BC, Berliner R, et al. Expert consensus recommendations for the performance of peripheral nerve blocks for headaches–a narrative review. Headache. 2013;53(3):437–46.
pubmed: 23406160
doi: 10.1111/head.12053
Renton T, Beke A. A narrative review of therapeutic peripheral nerve blocks for chronic orofacial pain conditions. J Oral Facial Pain Headache. 2022;36(1):49–58.
pubmed: 35298575
doi: 10.11607/ofph.3017
Nardi NM, Alvarado AC, Schaefer TJ. Infraorbital Nerve Block. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.; 2023.
Jurgens TP, Muller P, Seedorf H, Regelsberger J, May A. Occipital nerve block is effective in craniofacial neuralgias but not in idiopathic persistent facial pain. J Headache Pain. 2012;13(3):199–213.
pubmed: 22383125
pmcid: 3311831
doi: 10.1007/s10194-012-0417-x
Jan H, Jan M, Elena MK, Arne M. Greater occipital nerve block modulates nociceptive signals within the trigeminocervical complex. J Neurol Neurosurg Psychiatry. 2021;92(12):1335.
doi: 10.1136/jnnp-2021-326433
Robbins MS, Robertson CE, Kaplan E, Ailani J, Charleston L IV, Kuruvilla D, et al. The sphenopalatine ganglion: anatomy, pathophysiology, and therapeutic targeting in headache. Headache. 2016;56(2):240–58.
pubmed: 26615983
doi: 10.1111/head.12729
Mohamed B, Eman A-G, Eslam S, Ali A-H, Moiz B. Successful Treatment of Refractory Trigeminal Neuralgia with Sphenopalatine Ganglion Block (P2107). Neurology. 2018;90(15 Supplement):P2.107.
Kanai A, Suzuki A, Kobayashi M, Hoka S. Intranasal lidocaine 8% spray for second-division trigeminal neuralgia. Br J Anaesth. 2006;97(4):559–63.
pubmed: 16882684
doi: 10.1093/bja/ael180
Maizels M, Scott B, Cohen W, Chen W. Intranasal lidocaine for treatment of migraine: a randomized, double-blind, controlled trial. JAMA. 1996;276(4):319–21.
pubmed: 8656545
doi: 10.1001/jama.1996.03540040063034
Gonçalves DA, Speciali JG, Jales LC, Camparis CM, Bigal ME. Temporomandibular symptoms, migraine, and chronic daily headaches in the population. Neurology. 2009;73(8):645–6.
pubmed: 19704086
doi: 10.1212/WNL.0b013e3181b389c2
Goncalves DA, Bigal ME, Jales LC, Camparis CM, Speciali JG. Headache and symptoms of temporomandibular disorder: an epidemiological study. Headache. 2010;50(2):231–41.
pubmed: 19751369
doi: 10.1111/j.1526-4610.2009.01511.x
Romero-Reyes M, Pardi V, Akerman S. A potent and selective calcitonin gene-related peptide (CGRP) receptor antagonist, MK-8825, inhibits responses to nociceptive trigeminal activation: role of CGRP in orofacial pain. Exp Neurol. 2015;271:95–103.
pubmed: 25981890
doi: 10.1016/j.expneurol.2015.05.005
Akerman S, Romero-Reyes M. Preclinical studies investigating the neural mechanisms involved in the co-morbidity of migraine and temporomandibular disorders: the role of CGRP. Br J Pharmacol. 2020;177(24):5555–68. https://doi.org/10.1111/bph.15263 . Epub 2020 Oct 21. PMID: 32929719; PMCID: PMC7707098.
Cady RJ, Glenn JR, Smith KM, Durham PL. Calcitonin gene-related peptide promotes cellular changes in trigeminal neurons and glia implicated in peripheral and central sensitization. Mol Pain. 2011;7:94.
pubmed: 22145886
pmcid: 3267674
doi: 10.1186/1744-8069-7-94
Bevilaqua Grossi D, Lipton RB, Bigal ME. Temporomandibular disorders and migraine chronification. Curr Pain Headache Rep. 2009;13(4):314–8.
pubmed: 19586596
doi: 10.1007/s11916-009-0050-9
Fernandes G, Franco AL, Goncalves DA, Speciali JG, Bigal ME, Camparis CM. Temporomandibular disorders, sleep bruxism, and primary headaches are mutually associated. J Orofac Pain. 2013;27(1):14–20.
pubmed: 23424716
Franco AL, Goncalves DA, Castanharo SM, Speciali JG, Bigal ME, Camparis CM. Migraine is the most prevalent primary headache in individuals with temporomandibular disorders. J Orofac Pain. 2010;24(3):287–92.
pubmed: 20664830
Tchivileva IE, Ohrbach R, Fillingim RB, Greenspan JD, Maixner W, Slade GD. Temporal change in headache and its contribution to the risk of developing first-onset temporomandibular disorder in the Orofacial Pain: Prospective Evaluation and Risk Assessment (OPPERA) study. Pain. 2017;158(1):120–9.
pubmed: 27984525
pmcid: 5639910
doi: 10.1097/j.pain.0000000000000737
Goncalves DA, Camparis CM, Speciali JG, Castanharo SM, Ujikawa LT, Lipton RB, et al. Treatment of comorbid migraine and temporomandibular disorders: a factorial, double-blind, randomized, placebo-controlled study. J Orofac Pain. 2013;27(4):325–35.
pubmed: 24171182
doi: 10.11607/jop.1096
Kang JH. Effects on migraine, neck pain, and head and neck posture, of temporomandibular disorder treatment: Study of a retrospective cohort. Arch Oral Biol. 2020;114: 104718.
pubmed: 32334135
doi: 10.1016/j.archoralbio.2020.104718
Gonçalves DG, Camparis C, Franco A, Fernandes G, Speciali J, Bigal M. How to investigate and treat: migraine in patients with temporomandibular disorders. Curr Pain Headache Rep. 2012;16(4):359–64 (2012/08/01).
pubmed: 22610505
doi: 10.1007/s11916-012-0268-9
Penfield W, McNaughton F. Dural headache and innervation of the dura mater. Arch Neurol Psychiatry. 1940;44:43–75.
doi: 10.1001/archneurpsyc.1940.02280070051003
Ray BS, Wolff HG. Experimental studies on headache. Pain sensitive structures of the head and their significance in headache. Arch Surg. 1940;41:813–56.
doi: 10.1001/archsurg.1940.01210040002001
Daudia AT, Jones NS. Facial migraine in a rhinological setting. Clin Otolaryngol Allied Sci. 2002;27(6):521–5.
pubmed: 12472524
doi: 10.1046/j.1365-2273.2002.00628.x
Debruyne F, Herroelen L. Migraine presenting as chronic facial pain. Acta Neurol Belg. 2009;109(3):235–7.
pubmed: 19902820
Bartsch T, Goadsby PJ. Anatomy and physiology of pain referral in primary and cervicogenic headache disorders. Headache Currents. 2005;2:42–8.
doi: 10.1111/j.1743-5013.2005.20201.x
Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622 (02/0804/01/pmc-release).
pubmed: 28179394
pmcid: 5539409
doi: 10.1152/physrev.00034.2015
Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021–39.
pubmed: 34160823
doi: 10.1111/head.14153
Buse DC, Andrasik F. Behavioral medicine for migraine. Neurol Clin. 2009;27(2):445–65 (2009/05/01/).
pubmed: 19289225
doi: 10.1016/j.ncl.2009.01.003
Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358–73.
pubmed: 21883197
doi: 10.1111/j.1526-4610.2011.01990.x
Puledda F, Younis S, Huessler EM, Haghdoost F, Lisicki M, Goadsby PJ, et al. Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: a systematic review and network meta-analysis of the literature. Cephalalgia. 2023;43(3):3331024231151419.
pubmed: 36786357
doi: 10.1177/03331024231151419
Lipton RB, Croop R, Stock DA, Madonia J, Forshaw M, Lovegren M, et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023;22(3):209–17.
pubmed: 36804093
doi: 10.1016/S1474-4422(22)00517-8
Zhao YJ, Ong JJY, Goadsby PJ. Emerging treatment options for migraine. Ann Acad Med Singapore. 2020;49(4):226–35.
pubmed: 32419007
doi: 10.47102/annals-acadmed.sg.2019255
Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia. 2023;43(4):3331024231159366.
pubmed: 36855951
doi: 10.1177/03331024231159366
Ashina S, Mitsikostas DD, Lee MJ, Yamani N, Wang SJ, Messina R, et al. Tension-type headache. Nat Rev Dis Primers. 2021;7(1):24.
pubmed: 33767185
doi: 10.1038/s41572-021-00257-2
Hoffmann J, May A. Diagnosis, pathophysiology, and management of cluster headache. Lancet Neurol. 2018;17(1):75–83.
pubmed: 29174963
doi: 10.1016/S1474-4422(17)30405-2
Buhimschi CS, Weiner CP. Medications in pregnancy and lactation: part 1. Teratology. Obst Gynecol. 2009;113(1):166–88.
doi: 10.1097/AOG.0b013e31818d6788
Haanpää ML, Gourlay GK, Kent JL, Miaskowski C, Raja SN, Schmader KE, et al. Treatment considerations for patients with neuropathic pain and other medical comorbidities. Mayo Clin Proc Mayo Clinic. 2010;85(3 Suppl):S15–25.
doi: 10.4065/mcp.2009.0645
Soldin OP, Dahlin J, O’Mara DM. Triptans in pregnancy. Ther Drug Monit. 2008;30(1):5–9.
pubmed: 18223456
pmcid: 3644550
doi: 10.1097/FTD.0b013e318162c89b
Parikh SK, Delbono MV, Silberstein SD. Managing migraine in pregnancy and breastfeeding. Prog Brain Res. 2020;255:275–309.
pubmed: 33008509
doi: 10.1016/bs.pbr.2020.07.011
Fillingim RB, Ohrbach R, Greenspan JD, Knott C, Dubner R, Bair E, et al. Potential psychosocial risk factors for chronic TMD: descriptive data and empirically identified domains from the OPPERA case-control study. J Pain. 2011;12(11 Suppl):T46–60.
pubmed: 22074752
pmcid: 3233685
doi: 10.1016/j.jpain.2011.08.007
Fillingim RB, Ohrbach R, Greenspan JD, Sanders AE, Rathnayaka N, Maixner W, et al. Associations of psychologic factors with multiple chronic overlapping pain conditions. J Oral Facial Pain Headache. 2020;34:s85–100.
pubmed: 32975543
pmcid: 10165716
doi: 10.11607/ofph.2584
Slade GD, Greenspan JD, Fillingim RB, Maixner W, Sharma S, Ohrbach R. Overlap of five chronic pain conditions: temporomandibular disorders, headache, back pain, irritable bowel syndrome, and fibromyalgia. J Oral Facial Pain Headache. 2020;34:s15–28.
pubmed: 32975538
pmcid: 10073941
doi: 10.11607/ofph.2581
Crandall JA. An introduction to orofacial pain. Dent Clin North Am. 2018;62(4):511–23.
pubmed: 30189979
doi: 10.1016/j.cden.2018.05.001
Engel GL. The need for a new medical model: a challenge for biomedicine. Science. 1977;196(4286):129–36.
pubmed: 847460
doi: 10.1126/science.847460
Lipton RB, Stewart WF, Stone AM, Lainez MJ, Sawyer JP, Disability in Strategies of Care Study g. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) study: a randomized trial. JAMA. 2000;284(20):2599–605.
pubmed: 11086366
doi: 10.1001/jama.284.20.2599
Aggarwal VR, Fu Y, Main CJ, Wu J. The effectiveness of self-management interventions in adults with chronic orofacial pain: a systematic review, meta-analysis and meta-regression. Eur J Pain. 2019;23(5):849–65.
pubmed: 30620145
doi: 10.1002/ejp.1358
Carlson CR. Psychological considerations for chronic orofacial pain. Oral Maxillofac Surg Clin North Am. 2008;20(2):185–95 (vi).
pubmed: 18343324
doi: 10.1016/j.coms.2007.12.002
Schmidt JE, Carlson CR, Usery AR, Quevedo AS. Effects of tongue position on mandibular muscle activity and heart rate function. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108(6):881–8.
pubmed: 19773187
doi: 10.1016/j.tripleo.2009.06.029
Agha-Hosseini F, Sheykhbahaei N, Mirzaii-Dizgah I, Fatehi F. The efficacy of oral habit modification on headache. J Korean Assoc Oral Maxillofac Surg. 2017;43(6):401–6.
pubmed: 29333370
pmcid: 5756797
doi: 10.5125/jkaoms.2017.43.6.401
Menchel HF, Greene CS, Huff KD. Intraoral appliances for temporomandibular disorders: what we know and what we need to know. Front Oral Maxillofac Med. 2021. https://doi.org/10.21037/fomm-20-49 .
doi: 10.21037/fomm-20-49
Noma N, Watanabe Y, Shimada A, Usuda S, Iida T, Shimada A, et al. Effects of cognitive behavioral therapy on orofacial pain conditions. J Oral Sci. 2020;63(1):4–7.
pubmed: 33298629
doi: 10.2334/josnusd.20-0437
Vickers AJ, Vertosick EA, Lewith G, MacPherson H, Foster NE, Sherman KJ, et al. Acupuncture for chronic pain: update of an individual patient data meta-analysis. J Pain. 2018;19(5):455–74.
pubmed: 29198932
doi: 10.1016/j.jpain.2017.11.005
de Salles-Neto FT, de Paula JS, Romero J, Almeida-Leite CM. Acupuncture for pain, mandibular function and oral health-related quality of life in patients with masticatory myofascial pain: a randomised controlled trial. J Oral Rehabil. 2020;47(10):1193–201.
pubmed: 32668487
doi: 10.1111/joor.13055
Zhao L, Chen J, Li Y, Sun X, Chang X, Zheng H, et al. The long-term effect of acupuncture for migraine prophylaxis: a randomized clinical trial. JAMA Intern Med. 2017;177(4):508–15.
pubmed: 28241154
doi: 10.1001/jamainternmed.2016.9378
Zheng H, Gao T, Zheng QH, Lu LY, Hou TH, Zhang SS, et al. Acupuncture for patients with chronic tension-type headache: a randomized controlled trial. Neurology. 2022. https://doi.org/10.1212/WNL.0000000000200670 .
doi: 10.1212/WNL.0000000000200670
pubmed: 36914272
pmcid: 9670500
Edvinsson L. CGRP and migraine: from bench to bedside. Rev Neurol (Paris). 2021;177(7):785–90.
pubmed: 34275653
doi: 10.1016/j.neurol.2021.06.003
Michot B, Kayser V, Hamon M, Bourgoin S. CGRP receptor blockade by MK-8825 alleviates allodynia in infraorbital nerve-ligated rats. Eur J Pain. 2015;19(2):281–90.
pubmed: 25370954
doi: 10.1002/ejp.616
Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–9 (2014/04/01).
pubmed: 24526250
pmcid: 3962576
doi: 10.1007/s10067-014-2517-2
Hatfield E, Phillips K, Swidan S, Ashman L. Use of low-dose naltrexone in the management of chronic pain conditions: a systematic review. J Am Dent Assoc. 2020;151(12):891-902.e1.
pubmed: 33228882
doi: 10.1016/j.adaj.2020.08.019
Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013;13(2):214–23.
pubmed: 23789008
pmcid: 3684331
Ashina M. Migraine. N Engl J Med. 2020;383(19):1866–76.
pubmed: 33211930
doi: 10.1056/NEJMra1915327
Robbins MS. Diagnosis and management of headache: a review. JAMA. 2021;325(18):1874–85.
pubmed: 33974014
doi: 10.1001/jama.2021.1640
Goadsby PJ. Therapeutic prospects for migraine: can paradise be regained? Ann Neurol. 2013;74(3):423–34.
pubmed: 25813389
doi: 10.1002/ana.23996
Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache S. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021–39.
pubmed: 34160823
doi: 10.1111/head.14153
Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968–81.
pubmed: 19708964
doi: 10.1111/j.1468-1331.2009.02748.x